Brooklyn ImmunoTherapeutics, Inc. (BTX)

0.8038 +0.0060 (+0.75%) At close: 04:00PM EDT

Brooklyn ImmunoTherapeutics, Inc.

Building A
Suite 2100 140 58th Street
Brooklyn, NY 11220
United States
212 582 1199
https://www.brooklynitx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Lynn Sadowski Mason M.S.	Exec. VP of Clinical Operations	362.5k	N/A	1979
Mr. Ronald Guido M.S.	Chief Devel. Officer & Sec.	382.5k	N/A	1957
Dr. Howard J. Federoff M.D., Ph.D.	CEO, Pres & Director	N/A	N/A	1953
Ms. Sandra M. Gurrola	VP of Fin.	N/A	N/A	1967
Dr. Monil Shah M.B.A., Pharm.D.	Chief Operating Officer	N/A	N/A	N/A
Dr. Kevin A. D'Amour Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Jay Sial	Chief Admin. Officer	N/A	N/A	N/A
Dr. Roger Sidhu M.D.	Chief Medical Officer	N/A	N/A	N/A
Ms. Susan McClatchey	VP & Head of Quality	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.

Corporate governance

Brooklyn ImmunoTherapeutics, Inc.’s ISS governance QualityScore as of 1 February 2022 is 7. The pillar scores are Audit: 10; Board: 3; Shareholder rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.